Pangea Laboratory’s Post

💗 It’s Cervical Cancer Screening Month! 💗 It’s a vital time to emphasize the importance of early detection in the fight against cervical cancer. At Diagnostic Laboratory of Oklahoma, we proudly offer advanced testing options like SurePath® and ThinPrep® to healthcare providers, ensuring that patients receive thorough care that result in accurate reports. In addition to these supplies, we provide crucial laboratory testing like the human papillomavirus (HPV) test, which looks for the virus that can cause changes to the cervix. The Pap test, or Pap smear, is also essential as it detects precancers – cell changes on the cervix that might develop into cervical cancer if not treated appropriately. Together, these tests play a key role in early detection and effective management of cervical health. These innovative tests help facilitate precise diagnosis and contribute to better patient outcomes. Encouraging regular screenings can save lives, so let’s remind our friends and loved ones to prioritize their health! If you’re a healthcare provider looking for reliable testing solutions, we’re happy to help! Together, let’s make a difference in the lives of many. https://lnkd.in/g_2Eer-6 #CervicalCancerScreeningMonth #EarlyDetectionSavesLives #DLOCares

💡 Ovarian Cancer: Early Detection Can Save Lives Ovarian cancer can be difficult to detect in its early stages, but knowing the symptoms and your risk factors could make all the difference. 🌺 Common symptoms like bloating, pelvic pain, and changes in appetite should never be ignored. At Community Clinical Trials, we are dedicated to advancing research and providing access to cutting-edge treatments that can make a real impact. 🩺 Stay informed about early symptoms and explore the latest in ovarian cancer treatments. 👉 Learn more: https://bit.ly/4d9FO7s #OvarianCancer #WomensHealth #EarlyDetection #CancerAwareness #CommunityClinicalTrials #OvarianCancerSymptoms #WomensWellness

Most of us are well-versed in the immediate side effects of cancer treatment: nausea, fatigue, immune suppression. But did you know that these therapies can also disrupt hormone regulation, causing significant endocrine disorders? Patients who receive life-saving treatments like chemotherapy, radiation, or immunotherapy can develop serious issues such as adrenal insufficiency, thyroid dysfunction, or even steroid-induced diabetes. These complications, though often subtle at first, can drastically impact a patient’s quality of life if not caught early. This is where endo-oncology comes in. Afreen Shariff, MD, a leader in the field of endo-oncology, points out that this is one of the biggest gaps in current cancer care. Learn more with her and host, Amna Shabbir, MD, NBC-HWC, CPC: https://buff.ly/4dQKMGD

🔹 Did you know?? Bladder cancer is one of the most commonly diagnosed #cancers worldwide!! The most common form of #bladdercancer starts in the inner lining of the bladder cells (transitional cell carcinoma). Facts about Bladder Cancer !! 1. Smoking is the biggest Risk Factor 2. It is the 9th most diagnosed Cancer in the World. 3. Blood in the Urine is the most common symptom. 4. 1 in 4 Bladder Cancer Patients are women. 5. Bladder Cancer is highly treatable when caught early. Click here to know more - https://rb.gy/i0afwe For more information or to schedule a check-up, contact our medical team now!! Call: +91-7982403742 https://bit.ly/3oDBfic Whatsapp: +91-8800303633 https://rb.gy/smbs27 Email: info@medsurgeindia.com Website: www.medsurgeindia.com #BladderCancerAwareness #FightBladderCancer #KnowledgeIsPower #BladderCancer #cancerprevention #cancerawareness #cancercare #oncologist #medical #medsurgeindia #smoking #UrineInfection #urine #bestdoctors #besthospitals #cancerresearchuk

Why you should act on Prostate Cancer Awareness Month: 1 in 8 men will be diagnosed with prostate cancer in their lifetime. 1 in 6 African American men and 1 in 5 men with a family history are at increased risk. Early screening can lead to better outcomes and more effective treatment options. Why you should act on Prostate Cancer Awareness Month: 1 in 8 men will be diagnosed with prostate cancer in their lifetime. 1 in 6 African American men and 1 in 5 men with a family history are at increased risk. Early screening can lead to better outcomes and more effective treatment options. This month, use the opportunity to educate yourself and others about prostate cancer. Taking charge of your health starts with understanding your risks and having informed conversations with your healthcare provider at Prowers Medical Center Clinic. Schedule an appointment today at (719) 336-6767. #ProstateCancerAwareness

The evolution of multi-cancer early detection (MCED) testing has been a long time coming for oncologists like Dr. Daniel Mackey. “For the past 20 years, I've been looking for a way that we can screen patients for cancers at an earlier stage. With the multi-cancer early detection test from GRAIL (Galleri), this gives us an opportunity to find these patients and perhaps have more options available to ultimately treat these patients.” 🎥 WATCH to see how health systems like Mercy are integrating the Galleri test alongside recommended screenings to support more personal, proactive patient care. #MultiCancerEarlyDetection #CancerScreening #Oncology See Important Safety Information: http://bit.ly/33m8pFa Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Transforming Bladder Cancer diagnosis with the Randox MultiSTAT🔎 Triaging patients with unexplained haematuria at primary care is a huge challenge. Current gold standard methods, such as cystoscopy, involve invasive investigations that can lead to further complications and infections, and in most cases prove to be unnecessary. The Randox Bladder Cancer Biochip improves the likelihood of early detection with rapid results available in under 60 minutes. Requiring only a simple urine sample, the biochip helps to categorise patients into ‘high risk’ and ‘low risk’ groups for better patient management. With a high recurrence rate, the Randox Bladder Cancer biochip offers the ideal solution for simple and easy lifetime monitoring. Visit https://lnkd.in/ev8yngQi to find out more or get in contact at marketing@randox.com. #BladderCancer #RandoxMultiSTAT #CancerDiagnostics #HealthInnovation #EarlyDetection

📅 Mark your calendars for Sept 11, 2024, at 1 PM ET! 🕐 Join us for a powerful webinar on "Enhancing Colorectal Cancer Screening Through Effective Patient Navigation." 🎤 Learn how to integrate CPSTF recommendations to boost screening rates, improve cost-effectiveness, and provide comprehensive, culturally appropriate services. 🌟 Plus, discover ACS NNRT strategies for sustainability and collaboration with Comprehensive Cancer Control coalitions. 💪 Don't miss out (webinar will be recorded and archived)! #CancerPrevention #PatientNavigation #ACSNNRT https://lnkd.in/eWe2eYDt

👄Rare cancer Spotlight: Lip Cancer 👄A type of oral cancer that starts on the lips. In the United States, it affects 0.5 out of 100,000 people every year. 📌 Some of the risk factors for oral cancers like lip cancer are: 1. older age 2. tobacco use 3. heavy alcohol use 4. exposure to ultraviolet (UV) radiation over a long period of time 5. human papillomavirus (HPV) infection 📌 People with lip cancer may have symptoms like: 1. A sore or lesion on the lip that doesn’t go away 2. A lump or area of thickening on your lip 3. A white patch on your lip 4. Unexplained bleeding, pain or numbness affecting your lips Submit your related work at: cancer@genesispub.org For any queries whatsapp at: +1 (438) 699-5365 #LipCancerAwareness #SunSafety #Lipcancer #submissionopen #submitmanuscript #openaccess #cancer #researcher #postdoc #oncologist

Breast cancer remains a major global health challenge, and early detection is key to improving patient outcomes. EG BioMed’s Breast Cancer Monitoring Blood Test introduces a non-invasive, cutting-edge approach using advanced DNA methylation technology to detect cancer-related changes in the bloodstream. This enables early recurrence or metastasis detection and provides valuable insights into treatment effectiveness. As the exclusive distributor of EG BioMed’s innovative cancer testing solutions, YD Biopharma is proud to bring this next-generation breast cancer monitoring technology to more patients. With no time restrictions, minimal blood sample requirements, and high accuracy, this test is an essential tool for those with a family history of breast cancer, individuals undergoing treatment, or anyone concerned about their risk of recurrence. ✨ Early action can save lives. Take control of your health today with EG BioMed’s Breast Cancer Monitoring Blood Test. #BreastCancerAwareness #EarlyDetection #CancerScreening #PrecisionMedicine #DNAMethylation #CancerRecurrence #EGBioMed #YDBiopharma #BiotechInnovation #Oncology